What is LifeSprout?
Founded in September 2015 by distinguished scientists and surgeons from Johns Hopkins University, LifeSprout is at the forefront of developing advanced soft tissue restoration products. The company's innovative solutions are designed for both aesthetic and reconstructive applications, addressing critical needs arising from aging, cancer, and metabolic diseases. By harnessing breakthroughs in materials science, LifeSprout creates a suite of products that effectively mimic the body's natural tissues, aiming to restore form and function with minimal patient recovery time. The company's mission is deeply rooted in providing superior solutions driven by integrity, excellence, and creativity.
How much funding has LifeSprout raised?
LifeSprout has raised a total of $35.1M across 3 funding rounds:
Angel/Seed
$6.5M
Debt
$150K
Series A
$28.5M
Angel/Seed (2019): $6.5M with participation from Angel MD, Medytox, Inc., Kairos Venture Partners, Ginkgo Gofar, Triskelion Investments, and Maryland Technology Development Corporation
Debt (2020): $150K led by PPP
Series A (2020): $28.5M supported by Nexus Management Inc, Redmile Group , LLC, Abell Foundation Inc, and emeraldmanagers.com
Key Investors in LifeSprout
Maryland Technology Development Corporation
TEDCO is a Maryland-based organization that provides funding, resources, and connections to early-stage technology and life sciences companies. Their services include various funding programs, business resources, and support initiatives aimed at fostering innovation and entrepreneurship.
Nexus Management Inc
Nexus Management Inc is an investment firm that likely focuses on providing capital to companies with strong growth potential, potentially in the technology or healthcare sectors, given LifeSprout's focus.
Redmile Group , LLC
Redmile Group, LLC is a healthcare-focused investment firm that typically invests in biotechnology, pharmaceutical, and medical device companies, aligning with LifeSprout's innovative medical product development.
What's next for LifeSprout?
With the recent major strategic investment, LifeSprout is poised for accelerated development and market penetration. This capital infusion is expected to fuel the expansion of its product pipeline and enhance its go-to-market strategies, particularly within the competitive aesthetic and reconstructive surgery sectors. The company's focus on leveraging cutting-edge materials science to address unmet clinical needs positions it for significant growth. Future endeavors will likely involve scaling manufacturing capabilities, expanding clinical trials, and forging strategic partnerships to broaden its reach and impact on patient care.
See full LifeSprout company page
